ALEXZA PHARMACEUTICALS INC Earnings Conference Call (Q4 2007)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Mar 17 Calls Today's Calls

Call Details ALEXZA PHARMACEUTICALS INC Earnings Conference Call (Q4 2007) Mon, Mar 17, 2008, 5:00 pm Eastern Listen to the archived event audio About ALEXZA PHARMACEUTICALS INC (NasdaqGM:ALXA) Alexza Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing products for the treatment of acute and intermittent conditions primarily in the United States. Its technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery. The company has six product candidates in clinical development, including AZ-001 (Staccato prochlorperazine), which completed Phase 2 clinical trial for the acute treatment of migraine headaches; AZ-002 (Staccato alprazolam) that is in Phase 2 clinical trial for the acute treatment of panic attacks associated with panic disorder; AZ-004 (Staccato loxapine), which is in Phase 3 clinical trial for the treatment of acute agitation in patients with schizophrenia; and AZ-003 (Staccato fentanyl) that is in Phase 1 clinical trial for the treatment of patients with acute pain. Its clinical development products also comprise AZ-104 (Staccato loxapine), which is in Phase 2 clinical trial for the treatment of acute migraine headaches; and AZ-007 (Staccato zaleplon) that is in Phase 1 clinical trial for the treatment of insomnia in patients who have difficulty falling asleep, including patients who awake in the middle of the night and have difficulty falling back asleep. Alexza Pharmaceuticals has a development agreement with Autoliv ASP, Inc. for the development of heat packages that can be incorporated into proprietary single dose drug delivery device. The company was founded in 2000 as FaxMed, Inc. and changed its name to Alexza Corporation in June 2001. Later, it changed its name to Alexza Molecular Delivery Corporation in December 2001 and to Alexza Pharmaceuticals, Inc. in 2005. The company is based in Mountain View, California. More Info: Quote | Profile | Reports | Research | Msgs | Insider | Financials | Analyst Ratings